Deaths Reported Following Placement of Stomach Balloons for Obesity Treatment — Physician’s First Watch

Medical News |
August 11, 2017

Deaths Reported Following Placement of Stomach Balloons for Obesity Treatment

By Kelly Young

Edited by André Sofair, MD, MPH

The FDA is recommending that clinicians closely follow patients who've had liquid-filled intragastric balloon systems placed to treat obesity.

The alert follows reports of at least five deaths — four in patients with the Orbera Intragastric Balloon System and one with the ReShape Integrated Dual Balloon System — within days or weeks of the procedure.

The FDA has not been able to pinpoint the root cause of death, or whether the deaths are tied to the device or to the procedure to place the device. The agency notes there were two additional deaths related to treatment complications — gastric and esophageal perforations.

Earlier in 2017, the device makers added warnings to their labels noting an increased risk for acute pancreatitis and spontaneous balloon over-inflation.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.